Drugs / 3M-052-AF
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06613789 | Mar → Jun 2027 expected | HIV infectious disease | HIV Vaccine Trials Network | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06267872 | Oct 2024 → Dec 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT06334393 | Mar 2024 → Apr 2025 | Zika virus infectious disease | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 1 | NCT05903339 | Aug 2023 → Dec 2026 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04915768 | Jan 2023 → Jul 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT04177355 | Jan 2020 → Nov 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 1 | NCT06950177 Background | Jul 2025 → Aug 2026 overdue | COVID-19 | Duke University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06905275 Background | Jul 2025 → Jul 2027 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06680479 Background | Apr 2025 → Apr 2027 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Suspended | No outcome recorded |
| Phase 1 | NCT05983874 Background | Apr 2024 → Mar 2025 | HIV infectious disease | International AIDS Vaccine Initiative | Unknown | No outcome recorded |
| Phase 1 | NCT05781542 Background | Apr 2023 → Oct 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT05828095 Background | Apr 2023 → Jan 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT05471076 Background | Aug 2022 → Dec 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-04 | Valneva Austria GmbH | Results Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate valneva.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-11-04 | Valneva Austria GmbH | Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate valneva.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3M 052 AF | “A soluble, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated at 2 mg/mL, 0.55 mL per vial, in 20 mM Tris, 100 mM NaCl, pH 7.5 will be admixed with...” NCT05471076 ↗13“HVTN 300 is a first-in-human, open-label Phase 1 study evaluating the safety and immunogenicity of a CH505 TF chimeric (ch) Trimer adjuvanted with 3M-052-AF (a TLR7/8 agonist) + Alum.” PMID 41959788 ↗ Apr 2026 “The 3M-052-AF is provided by AAHI. 3M-052-AF is provided in 2mL vials, with a fill volume of 0.4mL at a concentration of 50µg/mL.” NCT05983874 ↗ “3M 052 AF is a clear-to-slightly hazy, colorless liquid.” NCT05983874 ↗ |
| Known as | AP 60-702 | “3M-052-AF (labeled as AP 60-702)” NCT06267872 ↗ |
| Action | Activate | “3M-052-AF (a TLR7/8 agonist)” PMID 41959788 ↗ Apr 2026 |
| Modality | Small molecule | “An aqueous formulation (AF) of the small molecule imidazoquinoline immune response modifier (IRM) 3M-052; toll-like receptor (TLR)7/8 agonist.” NCT06267872 ↗ |
| Route | Intramuscular | “Combination administered as two 0.5 mL doses via intramuscular injection into deltoid muscle.” NCT04915768 ↗ |